Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.

NCT00549913 is registered in ClinicalTrials.gov with Mesoblast, Ltd. as lead sponsor.

NCT NCT00549913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00549913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.
Lead sponsor
Mesoblast, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2007
Completion date
September 30, 2013
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease, spinal stenosis, spondylolisthesis